Homepage > Company > Media > Blog > 2020 > CHEMDIV STRENGTHENS CADD TEAM

CHEMDIV STRENGTHENS CADD TEAM

ChemDiv offers you CADD support as a complementary service for your discovery projects.

background

ChemDiv, Inc. is pleased to announce that Vladimir Berishvili (PhD medicinal chemistry) has joined Chemoinformatics and Proteochemometrics group. Vladimir graduated from Lomonosov Moscow State University, Chemistry Department in 2018, and brings his rich academic and industrial experience to ChemDiv's suite of Computer-Aided Drug Design (CADD) services.

Vladimir's addition to the group will help ChemDiv to extend the product portfolio and in silico design.

ChemDiv always strives to increase its expertise and capabilities in molecular modeling and protein-protein docking to characterize key molecular mechanisms in various diseases. These efforts are aimed at assisting its partners and customers to better and faster advance their research programs. ChemDiv's CADD support is a complementary service for its Discovery outSource TM) platform, which seamlessly integrates compound libraries, chemistry and biology preclinical services.

Read also

CHEMDIV IS NOW A DISCOVERY PARTNER WITH GWYNANT THERAPEUTICS AND CELYN THERAPEUTICS

ChemDiv has been selected as a discovery partner with Gwynant Therapeutics and Celyn Therapeutics and starts to work on novel small molecules for oncology targets.

Our covalent compound library is now available in a ready-to-dock format for BioSolveIT

ChemDiv,Inc.

Science & Nature reviews, August 2021 (2)

These are ChemDiv's reviews on Nature and Science Journal articles.

OCULAR DISEASES SMALL MOLECULES LIBRARY

ChemDiv presets a brand new OCULAR DISEASES SMALL MOLECULES LIBRARY (13,000 compounds, 7 targets, 4 diseases)For design of screening library we use emerging Targets.